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Introduction
Over a billion people worldwide smoke tobacco. Smoking exerts complex central and peripheral nervous system, behavioral, cardiovascular, and endocrine effects in humans (Vial 1986; Benowitz, 1988) . The addiction liability and pharmacological effects of smoking are due to nicotine. Pulmonary absorption of nicotine is extremely rapid, occurring at a rate similar to that after intravenous administration (Russell and Feyerabend, 1978) . In humans, absorbed nicotine is rapidly and extensively metabolized and eliminated to urine (Benowitz, 1988) .
Nicotine is mainly (70 -80%) metabolized to cotinine ( Fig. 1 ) by cytochrome P450 (CYP) 2A6 in humans (Nakajima et al., 1996) . Nicotine is also metabolized to nornicotine, via N-demethylation. In humans, 2-3% of nicotine is excreted as nornicotine in 24 hr urine (Kyerematen et al., 1990; Yamanaka et al., 2004) . Cundy and Crooks (1984) have reported that only small amounts of nornicotine (1.6%) were detected in 24 hr urine after [ 14 C]-nicotine was injected intraperitoneally into guinea pigs. After a single arterial dose of labeled nicotine in rats, it was found that nornicotine accounted for 8% of the total recovery of the administered dose in urine (Curvall and Kazemi Vala, 1993) . Therefore, the metabolism of nicotine to nornicotine would be a relatively minor pathway in the systemic clearance of nicotine. However, experimental animal studies revealed that nornicotine is present in brain at significant levels (approximately 20% of the total amount of nicotine and its metabolites) (Nordberg et al., 1989; Plowchalk et al., 1992; Nyback et al., 1994; Crooks et al., 1997) . The nornicotine concentration in brain was nearly equal to that of nicotine (Crooks et al., 1997) . These data indicated that nornicotine is a major metabolite of nicotine in brain. The half-lives of nornicotine in human plasma and rat brain are 6-fold and 3-fold longer than those of nicotine, respectively (Kyerematen et al., 1990; Ghosheh et al., 1999) . Since nornicotine is pharmacologically active (Zhang et al., 1990; Liu et al., 1993) , it may contribute to the neuropharmacological effects of nicotine and tobacco usage.
In our recent study (Yamanaka et al., 2004) , the urinary excretion profile of nicotine metabolites in subjects entirely lacking the CYP2A6 gene (poor metabolizers) was determined.
This article has not been copyedited and formatted. The final version may differ from this version. We found that the urinary excretion levels of nornicotine were similar between the poor metabolizers and extensive metabolizers who are homozygotes of the wild-type CYP2A6 allele (Yamanaka et al., 2004) , indicating the possibility that the enzyme responsible for the nornicotine formation might not be CYP2A6. In contrast, Murphy et al. (2005) recently reported that human CYP2A6 has a catalytic activity for nicotine N-demethylation. However, they did not investigate the other CYP isoforms. In the present study, we sought to identify the CYP isoform(s) involved in the nicotine N-demethylation to nornicotine in human liver microsomes.
Materials and Methods
Materials. Nicotine, nornicotine, and orphenadrine were purchased from Sigma-Aldrich (St.
Louis, MO). Coumarin, quinidine, S-mephenytoin, and phenobarbital were purchased from Wako Pure Chemical (Osaka, Japan). Nirvanol and ketoconazole were from Ultrafine (Manchester, England) and BIOMOL (Plymouth, PA), respectively. NADP + , glucose 6-phosphate, and glucose 6-phosphate dehydrogenase were purchased from Oriental Yeast (Tokyo, Japan). Pooled human liver microsomes (H161), microsomes from 15 individual human livers (H003, H006, H023, H030, H043, H056, H064, H066, H070, H089, H093, H095,   H112, HK23, and HK34), and recombinant human CYP1A1, CYP1A2, CYP1B1, CYP2A6,   CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, CYP3A5 and CYP3A7 expressed in baculovirus-infected insect cells (Supersomes) were purchased from BD Gentest (Woburn, MA). All recombinant CYPs were co-expressed with NADPH-CYP oxidoreductase. CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2E1, CYP3A4, CYP3A7 were also co-expressed with cytochrome b 5 . CYP1A2, CYP2A6, CYP2B6, CYP2D6, CYP2E1, and CYP3A4 protein contents in the microsomes of each human liver determined by immunoblot analyses were supplied by the manufacturer. The enzymatic activities for human CYP isoforms in each human liver microsomes, including phenacetin O-deethylation S-mephenytoin 4'-hydroxylation (CYP2C19), bufuralol 1'-hydroxylation (CYP2D6), chlorzoxazone 6-hydroxylation (CYP2E1), and testosterone 6β-hydroxylation (CYP3A4) were also supplied by the manufacturer. Anti-human CYP2A6 monoclonal antibody, anti-human CYP2B6 monoclonal antibody, rabbit anti-human CYP2D6 serum and rabbit anti-human CYP3A4 serum were from Daiichi Pure Chemicals (Tokyo, Japan). It was reported by the manufacturer that these antibodies specifically react with each CYP isoform. All other chemicals and solvents were of the highest grade commercially available.
Construction of expression systems of CYP2A6 and CYP2A13 in Escherichia coli.
A bicistronic construct consisting of the coding sequence of CYP2A6 followed by that of NADPH-cytochrome P450 reductase (NPR) was previously constructed in the pCW expression vector . The full-length human CYP2A13 cDNA was obtained by PCR based on the reference sequence (accession No. NM000766). A bicistronic construct consisting of the coding sequence of CYP2A13 followed by that of NADPH-cytochrome P450 reductase (NPR) was constructed using the CYP2A6/NPR expression vector. The 5'-termini of CYP2A13 cDNA was modified to achieve a high expression level in a similar way to that of the CYP2A6/NPR expression vector. Nucleotide sequences were confirmed by DNA sequence analysis (Long-Read Tower DNA sequencer, Amersham Pharmacia Biotech, Buckinghamshire, UK). These plasmids were transformed to Escherichia coli JM109. Escherichia coli membranes expressing CYP2A6/NPR or CYP2A13/NPR were prepared, and the P450 content, protein concentration, and NADPH-cytochrome c reduction activity were determined according to the methods described previously . CYPs require a 1-to 3-fold excess amount of NPR to show the full activity in a reconstituted system (Soucek, 1999) .
The molar ratios of the NPR to the CYP2A6 and CYP2A13 were confirmed to be over 4 in the membrane preparations in the present study.
Preparation of human brain microsomes from striatum. This study was approved by the Kanazawa University (Kanazawa, Japan). Human striatum samples (n = 3; 23, 79, and 82 years old) were obtained from autopsy materials which were discarded after pathological investigations. The post-mortem delay was less than 24 hr. After dissection, the samples were immediately frozen in liquid nitrogen and stored at -80°C. Microsomes were prepared as described by Voirol et al. (2000) with slight modifications, and were stored at -80°C until use.
Nicotine N-demethylation assays. The nicotine N-demethylase activity was determined by LC-MS/MS. A typical incubation mixture (200 µl total volume) contained 0.5 mg/ml human liver microsomes (or 20 pmol/ml Supersomes, 50 pmol/ml Escherichia coli membrane, or 1 mg/ml human striatal microsomes), 50 mM potassium phosphate buffer (pH 7.4), an NADPH-generating system (0.5 mM NADP + , 2 mM glucose 6-phosphate, 1 U/ml glucose 6-phosphate dehydrogenase, 4 mM MgCl 2 ), and nicotine (20 and 100 µM for human liver microsomes; 200 µM for recombinant CYPs and human striatal microsomes). After 2 min pre-incubation, the reactions were initiated by the addition of the NADPH-generating system and were incubated at 37°C for 20 min. The reactions were terminated by 100 µl of methanol.
After the centrifugation at 9,000 g for 5 min, the supernatant was filtered with a 0.22 µm filter (Ultrafree®-MC centrifugal filter unit, Millipore, Eschborn, Germany). Aliquots of 5 µl were injected into the LC-MS/MS system.
LC-MS/MS analysis.
Nicotine and nornicotine were determined by LC-MS/MS as described previously (Yamanaka et al., 2004) , with minor modifications. Liquid chromatography (LC) was performed using an HP 1100 system including a binary pump, an automatic sampler, and a column oven (Agilent Technologies, Waldbronn, Germany), which was equipped with a without the NADPH-generating system was subtracted to correct the activity.
Kinetic analyses of nicotine N-demethylase activities in human liver microsomes or recombinant CYP isoforms.
The kinetic studies were performed using pooled human liver microsomes or recombinant CYPs. When determining the kinetic parameters, the substrate concentration ranged from 10 µM to 2000 µM for human liver microsomes, and from10 µM to 1000 µM for recombinant CYPs. The kinetic parameters were estimated from the fitted curves using a KaleidaGraph computer program (Synergy Software, Reading, PA) designed for nonlinear regression analysis.
Inhibition Study. The nicotine N-demethylase activity in pooled human liver microsomes at 100 µM nicotine was determined in the presence of inhibitors for CYP2A6, CYP2B6, CYP2D6 or CYP3A4. Coumarin (100 µM), orphenadrine (500 µM), quinidine (10 µM) and ketoconazole (1 µM) were used as specific inhibitors for CYP2A6 (Yun et al., 1991) , CYP2B6 (Reidy et al., 1989) , CYP2D6 (Broly et al., 1989) and CYP3A4 (Newton et al., 1995) , respectively. All inhibitors were dissolved in methanol so that the final concentration of solvent in the incubation mixture was <1%. For the inhibition study with coumarin, quinidine and ketoconazole, the assays were performed as described above. For the inhibition study with orphenadrine (mechanism based inhibitor), the incubation mixture including the inhibitor was S-mephenytoin N-demethylation assay. S-mephenytoin N-demethylase activity was determined by HPLC as described elsewhere (Ko et al., 1998) 10 mM S-mephenytoin. After 2 min pre-incubation, the reactions were initiated by the addition of the NADPH-generating system and were incubated at 37°C for 60 min. The reactions were terminated by 100 µl of ice-cold CH 3 CN and added phenobarbital (25 ng) as an internal standard. The reaction mixtures were centrifuged at 9,000 g for 5 min, and aliquots of 100 µl were injected into the HPLC system.
HPLC analyses were performed using a PC-980 pump (Jasco, Tokyo, Japan), UV-970 intelligent UV/VIS detector (Jasco), AS-950-10 autosampler (Jasco), D-2500 integrator (Hitachi, Tokyo, Japan), and CTO-6A column oven (Shimadzu, Kyoto, Japan) equipped with an Capcell PAK C18 UG120 (4.6 x 250 mm; 5 µm) column (Shiseido, Tokyo, Japan). The eluent was monitored at 204 nm. The mobile phase was 25% CH 3 CN/50 mM potassium phosphate buffer (pH 3.8). The flow rate was 1.0 ml/min and the column temperature was 35°C. The retention times of nirvanol, phenobarbital, and S-mephenytoin were 9.5 min, 11.4 min, and 16.7 min, respectively. The quantification of nirvanol was performed by comparing the HPLC peak heights to those of an authentic standard with reference to an internal standard.
Statistical Analysis. Data are the mean of duplicate measurements. Correlations between the nicotine N-demethylase activity and immunoreactive CYP contents or enzymatic activities in microsomes from 15 human livers were determined by Pearson's product-moment method.
Results
Nicotine N-demethylase activity in human liver microsomes. The formation of nornicotine from nicotine in the pooled human liver microsomes increased in protein concentration-and time-dependent manners. The formation was linear at least at 1 mg/ml microsomal protein and 30-min incubation. Unless specified, the standard incubation mixture containing 0.5 mg/ml microsomal protein was incubated at 37°C for 20 min. The kinetics of nicotine N-demethylation in the pooled human liver microsomes was biphasic (Fig. 3) 
Inhibition analyses. The effects of chemical inhibitors or antibodies against the CYP isoforms
on the nicotine N-demethylase activities in pooled human liver microsomes were determined at 100 µM nicotine (Fig. 6) . The activity was inhibited by coumarin (67% of the control activity), anti-CYP2A6 antibody (40% of the control activity), orphenadrine (28% of the control activity), and anti-CYP2B6 antibody (30% of the control activity). In contrast, the activity was not affected by quinidine, anti-CYP2D6 serum, ketoconazole, or anti-CYP3A4 serum.
Next, two samples of human liver microsomes, H003 (CYP2A6 abundant) and H112
(CYP2B6 abundant), were also used for the inhibition study of CYP2A6 and CYP2B6 (Table 2) .
The nicotine N-demethylase activity in human liver microsomal sample H003 (CYP2A6 antibody moderately inhibited the activity (35 and 64% of control activity, respectively). The inhibition percentages for the nicotine N-demethylase activity at 100 µM nicotine by coumarin, anti-CYP2A6 antibody, and orphenadrine were almost the same as those at 20 µM nicotine. It is noteworthy that the activity was considerably inhibited by anti-CYP2B6 antibody (28% of control activity). The nicotine N-demethylase activity in human liver microsomal sample H112 (CYP2B6 abundant) at 20 µM nicotine was weakly inhibited by coumarin (81% of control activity) and anti-CYP2A6 antibody (53% of control activity). In contrast, the activity was markedly inhibited by orphenadrine and anti-CYP2B6 antibody (30% and 26% of control activity, respectively). The nicotine N-demethylase activity at 100 µM of nicotine was also inhibited to a similar extent.
Contributions of CYP2A6 and CYP2B6 to nicotine N-demethylase activity in human liver
microsomes. The contributions of CYP2A6 and CYP2B6 to the nicotine N-demethylase activity in microsomes from 8 human livers were determined. The nicotine N-demethylase activity in the human liver microsomes (H003, H023, H030, H056, H066, H070, H112 and HK34) at 20 µM nicotine ranged from 2.8 to 7.9 pmol/min/mg protein (Fig. 7) . The immunochemically determined contents of CYP2A6 and CYP2B6 (pmol/mg) supplied by the manufacturer are shown in Fig. 7 . The V rec-CYP2A6 and V rec-CYP2B6 values were 0.07 and 0.18 pmol/min/pmol P450, respectively. Consequently, the contributions of CYP2A6 and CYP2B6
to the nicotine N-demethylase activity in human liver microsomes that are relatively CYP2A6 abundant (those except H112) were estimated as 49 to 104% and 13 to 41%, respectively (Fig.   7 ). In contrast, the contributions in CYP2A6 and CYP2B6 in human liver microsomal sample (H112), which is CYP2B6 abundant, were estimated as 3% and 123%, respectively. The sum of the percentages of the contributions of CYP2A6 and CYP2B6 ranged from 64% to 126%. reported that the formed nornicotine was about 5% of the total metabolism of nicotine (Murphy et al., 2005) , the absolute activity was unknown. In the present study, we first determined the specific activity for the nicotine N-demethylation in recombinant CYP2A6 (Supersomes), and its CLint was calculated as 5.1 nl/min/pmol P450. It is emphasized that recombinant CYP2B6 revealed 2.5-fold higher CLint than did CYP2A6. The Km values in the recombinant CYP2A6
and CYP2B6 were close to those for the high-and low-affinity components in human liver microsomes, respectively. At a relatively low substrate concentration (20 µM nicotine, lower than the Km value for CYP2A6), the nicotine N-demethylase activity was significantly correlated with the content or specific activity for CYP2A6. In addition, it was also correlated with the CYP2B6 specific activity. We confirmed that no significant correlation was observed between CYP2A6 and CYP2B6 in these specific activities and protein contents in the panel of human liver microsomes used in this study (data not shown). At a relatively high substrate concentration (100 µM), the nicotine N-demethylase activity was significantly correlated with the content or specific activity for CYP2B6. These results suggested that the contributions of CYP2A6 and CYP2B6 to the nicotine N-demethylation would be significant at low and high substrate concentrations, respectively. Murphy et al. (2005) reported that CYP2A13 also could catalyze the nicotine N-demethylation more efficiently than CYP2A6, although the absolute enzymatic activities This article has not been copyedited and formatted. The final version may differ from this version. were not determined. In this study, we found that recombinant CYP2A13 exhibited a 17-fold higher CLint value than recombinant CYP2A6 expressed in Escherichia coli. However, it has been reported that the expression level of CYP2A13 mRNA (7 ± 6 attomoles /mg RNA) was much lower than that of CYP2A6 mRNA (13,000 ± 12,000 attomoles /mg RNA) in human livers (Su et al., 2000) . Although we can not quantify the expression levels of CYP2A13 and CYP2A6 proteins in human livers since antibodies specific for each isoform are not available, it is considered that the expression level of CYP2A13 protein would also be much lower than that of CYP2A6 protein. Thus, the role of CYP2A13 in the nornicotine formation would be mostly insignificant in human livers.
The nicotine N-demethylase activity in human liver microsomes at a nicotine concentration of 100 µM was also significantly correlated with the testosterone 6β-hydroxylase activity (the specific activity for CYP3A4). In the panel of human liver microsomes used in this study, a fortuitous correlation between the testosterone 6β-hydroxylase activity and CYP2B6 protein content (r = 0.809, p < 0.001) was also observed. Furthermore, the nicotine N-demethylase activity in human liver microsomes was not inhibited by ketoconazole and anti-CYP3A4 serum.
These results suggested that the involvement of CYP3A4 in the nicotine N-demethylase activity in human liver microsomes would be negligible.
Quantitative analysis of the contributions of each CYP isoform using the activities by recombinant CYPs and contents of each CYP isoform in human liver microsomes revealed that the contributions of CYP2A6 and CYP2B6 to the nicotine N-demethylation would be dependent on the individual expression levels of these isoforms. The sum of the percentage contributions of CYP2A6 and CYP2B6 ranged from 64% to 126%, indicating that these CYP isoforms are the major enzymes responsible for the nicotine N-demethylation in humans. One limitation of this prediction method is that the CYP contents were measured by immunoblot analysis. Immunoblot analysis can not distinguish between active and inactive protein. Another prediction method is using the RAF (relative activity factor) with specific activities for each CYP (Crespi, 1995 , Nakajima et al., 1999 . However, the RAF method for predicting the
CYP2B6 contribution was not successful (the estimated contributions of CYP2B6 in all human
This article has not been copyedited and formatted. The final version may differ from this version. Previously, we demonstrated that the urinary excretion levels of nornicotine in subjects entirely lacking the CYP2A6 gene were similar to those in normal subjects, suggesting that the involvement of CYP2A6 in the nornicotine formation was slight (Yamanaka et al., 2004) .
However, the present in vitro study demonstrated that CYP2A6 has a significant catalytic activity for nornicotine formation as a high affinity component. Therefore, the nornicotine formed in the subjects lacking CYP2A6 would result from the compensatory role of CYP2B6.
In the present study, the CLint for the nornicotine formation in human liver microsomes was calculated as 0.3 µl/min/mg. Previously, we demonstrated that the CLint for the cotinine formation in human liver microsomes was 1.6 µl/min/mg (Nakajima et al., 1996) . The difference in the intrinsic clearances between the two metabolic pathways would reflect the metabolic profile of nicotine in human urine, i.e. nornicotine: 2 -3% and cotinine: 70 -80% (Benowitz et al., 1994 ).
Nornicotine is a major metabolite of nicotine in brain (Crooks et al., 1997) . In the human brain, CYP2B6 protein is expressed in various regions including the occipital cortex, hippocampus, striatum, cerebellar vermis, cerebellar hemisphere (Gervot et al., 1999; Miksys et al, 2003) . In addition, Miksys and Tyndale (2004) recently reported that CYP2A6 mRNA is also expressed in various regions of the human brain. In particular, the expression levels of CYP2B6 protein and CYP2A6 mRNA are high in the striatum (Miksys et al, 2003; Miksys and Tyndale 2004) . These backgrounds prompted us to investigate the nicotine N-demethylase activities in human brain microsomes from striatum. Consequently, the nicotine N-demethylase activity was detected in human brain microsomes from striatum. The present study demonstrated that nornicotine in brain could have originated from the nicotine N-demethylation locally in the brain, in addition to the nornicotine that is formed in the liver and subsequently This article has not been copyedited and formatted. The final version may differ from this version. passes the blood-brain barrier. It has been reported that nicotine can induce CYP2B in rat brain (Anandatheerthavarada et al., 1993; Miksys et al., 2000) . In smokers, the a higher level of CYP2B6 protein in the brain was detected than in non-smokers, suggesting that nicotine can also induce human CYP2B6 in the brain (Miksys et al., 2003) . Until now, there has been no information on whether CYP2A6 is inducible by nicotine. Generally, the induction of CYP2B is mediated by constitutive androstane receptor (CAR) or pregnane X receptor (PXR). These receptors usually cross-talk with each other toward target genes. Recently, Lamba et al. (2004) reported that nicotine could activate human PXR. Collectively, the induction of CYP2B6 by nicotine would enhance the metabolism of nicotine to nornicotine.
In summary, we found that CYP2A6 and CYP2B6 catalyze the nornicotine formation from nicotine in human liver microsomes. These contributions would be dependent on the individual expression levels of CYP2A6 and CYP2B6. The control activity in the pooled human liver microsomes was 16.5 pmol/min/mg protein.
Each column represents the mean of duplicate determinations. This article has not been copyedited and formatted. The final version may differ from this version. b Phenacetin O-deethylase activity (CYP1A2), coumarin 7-hydroxylase activity (CYP2A6), S-mephenytoin N-demethylase activity (CYP2B6), diclofenac 4'-hydroxylase activity (CYP2C9), S-mephenytoin 4'-hydroxylase activity (CYP2C19), bufuralol 1'-hydroxylase activity (CYP2D6), chlorzoxazone 6-hydroxylase activity (CYP2E1) and testosterone 6β-hydroxylase activity (CYP3A4) were measured as specific activities for each CYP isoform.
This article has not been copyedited and formatted. The final version may differ from this version. 
